About this Journal Submit a Manuscript Table of Contents

Nonsystemic Treatment of Metastatic Urologic Malignancies: Basic and Clinical Research

Call for Papers

Nowadays, the majority of urologic malignancies are diagnosed in a localized stage for which a treatment with curative intention is possible. Nevertheless, some patients will be diagnosed with metastatic disease or will develop metastases after a treatment with curative intent. With the exception of testicular cancer, metastatic urologic malignancies are considered as incurable. In this stage, systemic cytotoxic treatments are administrated as palliative treatment to delay progression and improve survival. However, these treatments are associated with significant morbidity and even mortality.

Emerging data from kidney and prostate cancer indicate that maximum local treatment of the primary tumor prolongs progression-free, cancer-specific, and overall survival. Furthermore, local treatment of the metastasis by surgical removal (“metastasectomy”) or by high-dose stereotactic radiotherapy can be beneficial to delay progression and to delay the initiation of systemic cytotoxic treatments.

We invite investigators to submit original basic and clinical research as well as review articles on nonsystemic treatments of different urologic malignancies. These malignancies include prostate cancer, kidney cancer, muscle-invasive bladder cancer, penile cancer, and testicular cancer. We are particularly interested in papers describing basic translational research on the molecular biology of metastatic urologic malignancies that can explain why nonsystemic treatments might be beneficial. Furthermore, papers reporting on clinical outcomes of nonsystemic treatments are of high impact for the urologic, radiotherapeutic, and oncologic community treating urologic malignancies. Potential topics include, but are not limited to:

  • Recent developments in molecular biology of metastatic urologic malignancies and its potential impact on nonsystemic treatments
  • Recent developments in imaging of metastatic urologic malignancies: detection of metastases in an early stage
  • Elucidating the role of the abscopal effect in metastatic urologic malignancies
  • Research on biomarkers that can predict outcome of nonsystemic treatments in urologic malignancies
  • Clinical outcome of local treatment of the primary tumor in metastatic urologic malignancies
  • Clinical outcome of local treatment of the metastases in metastatic urologic malignancies
  • Health economic aspects on nonsystemic treatments of urologic malignancies

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/urology/nbcr/ according to the following timetable:

Manuscript DueFriday, 17 October 2014
First Round of ReviewsFriday, 9 January 2015
Publication DateFriday, 6 March 2015

Lead Guest Editor

  • Nicolaas Lumen, Department of Urology, Ghent University Hospital, Ghent, Belgium

Guest Editors

  • Gert De Meerleer, Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
  • Achilles Ploumidis, Department of Urology, Athens Medical Centre, Athens, Greece
  • Franklin Kuehhas, Department of Urology, Medical University of Vienna, General Hospital Vienna, Vienna, Austria